MedTrace Logo

The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children

NCT04699097 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2021-01-07

No results posted yet for this study

Summary

Azithromycin (AZ) is used in the pediatric group in COVID-19 diseas. It has been reported to cause prolongation in the QT interval in adult age group. The aim of this study is to evaluate the effect of AZ on ventricular repolarization in COVID-19 positive pediatric patients.

METHOD The study was conducted prospectively in July-August 2020. COVID-19 pediatric patients who received AZ treatment were included in the study. ECG was obtained before treatment and on the 1st, 3rd and 5th days after the treatment. Measurements were made with Image J program®. QTmax, QTmin, Tp-emax, Tp-emin intervals were measured. QTcmax, QTcmin, Tp-ecmax, Tp-ecmin, QTcd, Tp-ecd, and QTc / Tp-ec ratios were calculated with Bazett formula.

Conditions

  • Azithromycin Adverse Reaction
  • Covid19
  • Long QT Syndrome

Interventions

DRUG

Azithromycin

250 mg tablet, 5 ml / 200 mg 30 ml suspension

Sponsors & Collaborators

  • Kayseri City Hospital

    lead OTHER_GOV

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2020-09-01
Completion
2020-11-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04699097 on ClinicalTrials.gov